+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Opioids Market - Global Forecast 2025-2032

  • PDF Icon

    Report

  • 192 Pages
  • October 2025
  • Region: Global
  • 360iResearch™
  • ID: 5977695
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior leaders in the opioid market face a rapidly changing landscape marked by evolving regulations, clinical standards, and operational demands. Navigating this complexity requires clear, actionable intelligence tailored for strategic advancement and ongoing compliance in a dynamic healthcare environment.

Market Snapshot: Opioid Market Size and Growth Trajectory

The global opioid market achieved a valuation of USD 21.53 billion in 2024 and is forecasted to reach USD 22.44 billion in 2025, representing an annual growth rate of 4.21%. By 2032, the market is projected to stand at USD 29.96 billion, highlighting sustained global demand for opioid-based therapies. This growth continues in light of tightening compliance requirements and shifting societal expectations, reinforcing the need for persistent innovation and regulatory agility across all markets. As the opioid market remains a cornerstone of pain management worldwide, organizations must stay vigilant amid changing external drivers and stakeholder pressures.

Scope & Segmentation: Comprehensive Analysis of the Opioid Market

This report offers granular segmentation and regional insights, enabling executive decision-makers to identify strategic opportunities and mitigate operational risks across the opioid value chain:

  • Opioid Types: Analysis encompasses natural opiates such as morphine and codeine, semi-synthetic alternatives including hydrocodone and oxycodone, as well as synthetic variants like fentanyl and methadone. Each category presents unique risk profiles and application nuances, essential for optimizing product portfolios and mitigating exposure to regulatory scrutiny.
  • Modes of Administration: Examines oral, parenteral, and transdermal systems, considering their implications for manufacturing, compliance, and supply chain logistics.
  • Application Areas: Covers anesthesia, cough suppression, and pain management in acute and chronic scenarios, guiding prioritization for R&D and operations in line with clinical trends and treatment modalities.
  • End Users: Investigates hospitals, clinics, home healthcare settings, and research institutes, each demanding tailored channel strategies and offering distinctive partnership possibilities.
  • Geographic Coverage: Delivers analysis across the Americas, Europe, Middle East, Africa, and Asia-Pacific, supporting detailed planning for expansion, compliance, or risk mitigation in diverse regulatory landscapes.
  • Major Companies: Profiles Hikma Pharmaceuticals PLC, Pfizer Inc., AbbVie Inc., Alvogen, Apotex Inc., Daiichi Sankyo Company, Fresenius SE, Indivior PLC, Johnson & Johnson, Mallinckrodt plc, Nutriband Inc., Purdue Pharma, Teva Pharmaceutical, Viatris Inc., and additional market innovators advancing new strategies and operational frameworks.

Key Takeaways for Senior Leaders

  • Abuse-deterrent formulation technologies are reshaping safety standards, demanding tighter collaboration between research and compliance teams to protect public health and ensure regulatory approval.
  • Adoption of digital prescription monitoring and integrated patient data platforms enhances traceability, strengthens compliance protocols, and drives modernization of IT infrastructures.
  • Regulatory changes continue to drive the development of robust risk management systems, helping organizations maintain reputational trust and effective governance across divisions.
  • Strategic diversification into non-opioid pain management and integrated care options supports long-term development and future-resilience amid shifting regulatory priorities.
  • Vertical integration and diversified sourcing are prioritized to safeguard supply continuity, support accelerated innovation, and maintain competitive agility under evolving market pressures.

Tariff Impact: Navigating Supply Chain and Pricing Pressures

Heightened tariffs in the United States on opioid precursors and finished products are altering established supply networks and increasing procurement costs. In response, firms are revising sourcing structures, recalibrating pricing strategies, and deploying smarter customs processes to manage trade-related uncertainties. Enhanced operational agility is critical for sustaining partnerships and securing reliable access in this volatile environment.

Methodology & Data Sources

This assessment relies on a two-stage methodology: systematic secondary research from regulatory filings, clinical trials, and patent databases, followed by targeted interviews with clinicians, pharmacologists, and logistics experts. Comprehensive statistical validation underpins actionable recommendations for executive stakeholders.

Why This Report Matters: Action-Oriented Intelligence for Senior Decision-Makers

  • Empowers executives with insights into regulatory adjustments, technological innovation, and shifting stakeholder requirements shaping market opportunities and risks.
  • Detailed segmentation and regional perspectives direct focused investment and strategic expansion across regions with differing compliance profiles.
  • Provides concise, evidence-based recommendations to support the reinforcement of compliance structures and to sharpen competitive positioning in a rapidly changing sector.

Conclusion

Organizational responsiveness and informed leadership are vital as the opioid sector transforms. The intelligence provided in this report supports sound, future-focused action and responsible market participation as new challenges and opportunities develop.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Surge in telemedicine-based medication-assisted treatment for opioid use disorder
5.2. Widespread integration of AI-driven prescription drug monitoring programs to prevent misuse
5.3. Accelerated launch of generic opioid analgesics following landmark patent expirations
5.4. Growing adoption of abuse-deterrent formulations with novel polymer matrix technologies
5.5. Expansion of community pharmacy naloxone distribution through state standing orders
5.6. Rising collaborations between payers and providers on value-based opioid treatment contracts
5.7. Intensified regulatory scrutiny on illicit synthetic opioid analogues like fentanyl and carfentanil
5.8. Shift towards non-opioid pain management alternatives including CGRP and TRPV1 inhibitors
5.9. Enhanced real-world evidence studies demonstrating cost effectiveness of MOUD programs
5.10. Emerging legal challenges around opioid litigation settlements and fund allocation transparency
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Opioids Market, by Opioid Types
8.1. Natural Opiates
8.1.1. Codeine
8.1.2. Morphine
8.2. Semi-Synthetic Opioids
8.2.1. Hydrocodone
8.2.2. Oxycodone
8.3. Synthetic Opioids
8.3.1. Fentanyl
8.3.2. Methadone
9. Opioids Market, by Mode of Administration
9.1. Oral Administration
9.1.1. Capsules
9.1.2. Tablets
9.2. Parenteral Administration
9.2.1. Intramuscular
9.2.2. Intravenous
9.3. Transdermal Administration
10. Opioids Market, by Application
10.1. Anesthesia
10.1.1. General Anesthesia
10.1.2. Regional Anesthesia
10.2. Cough Suppression
10.3. Pain Management
10.3.1. Acute Pain
10.3.2. Chronic Pain
11. Opioids Market, by End-User
11.1. Healthcare Facilities
11.1.1. Clinics
11.1.2. Hospitals
11.2. Home Healthcare
11.3. Research Institutes
12. Opioids Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Opioids Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Opioids Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Hikma Pharmaceuticals PLC
15.3.2. Pfizer Inc.
15.3.3. AbbVie Inc.
15.3.4. Alvogen
15.3.5. Apotex Inc.
15.3.6. Biesterfeld SE
15.3.7. Daiichi Sankyo Company, Limited
15.3.8. Elite Pharmaceuticals, Inc.
15.3.9. Endo International plc
15.3.10. Fresenius SE & Co. KGaA
15.3.11. Humanwell Healthcare (Group) Co., Ltd.
15.3.12. Indivior PLC
15.3.13. Johnson & Johnson Services, Inc.
15.3.14. Johnson Matthey Group
15.3.15. Kyowa Hakko Kirin Co. Ltd.
15.3.16. Mallinckrodt plc
15.3.17. Nutriband Inc.
15.3.18. Piramal Pharma Limited
15.3.19. Purdue Pharma L.P.
15.3.20. QuVa Pharma, Inc
15.3.21. SCA Pharma
15.3.22. Spectrum Chemical Mfg. Corp.
15.3.23. Teva Pharmaceutical Industries Ltd.
15.3.24. Tofigh Daru Research & Engineering Company
15.3.25. Verve HumanCare Laboratories
15.3.26. Viatris Inc.

Samples

Loading
LOADING...

Companies Mentioned

The key companies profiled in this Opioids market report include:
  • Hikma Pharmaceuticals PLC
  • Pfizer Inc.
  • AbbVie Inc.
  • Alvogen
  • Apotex Inc.
  • Biesterfeld SE
  • Daiichi Sankyo Company, Limited
  • Elite Pharmaceuticals, Inc.
  • Endo International plc
  • Fresenius SE & Co. KGaA
  • Humanwell Healthcare (Group) Co., Ltd.
  • Indivior PLC
  • Johnson & Johnson Services, Inc.
  • Johnson Matthey Group
  • Kyowa Hakko Kirin Co. Ltd.
  • Mallinckrodt plc
  • Nutriband Inc.
  • Piramal Pharma Limited
  • Purdue Pharma L.P.
  • QuVa Pharma, Inc
  • SCA Pharma
  • Spectrum Chemical Mfg. Corp.
  • Teva Pharmaceutical Industries Ltd.
  • Tofigh Daru Research & Engineering Company
  • Verve HumanCare Laboratories
  • Viatris Inc.

Table Information